NXTC: NextCure, Inc.
About
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Current Value
$1.301 Year Return
Current Value
$1.301 Year Return
Key Details
Market Cap
$36.13M
P/E Ratio
-0.62
1Y Stock Return
3.20%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
0.5
Strategies that include NXTC
Stock's related to NXTC
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AMTX | 26.88% | $203.41M | -13.07% | 0.00% |
| GRAL | 25.83% | $508.58M | -3.65% | 0.00% |
| CHX | 25.57% | $5.96B | +6.36% | 1.17% |
| ABM | 24.98% | $3.54B | +37.92% | 1.58% |
| CLRB | 24.74% | $64.10M | -28.18% | 0.00% |
| SCVL | 24.72% | $919.83M | +43.25% | 1.53% |
| PKE | 24.36% | $300.03M | -1.51% | 3.30% |
| DAWN | 24.31% | $1.35B | +12.38% | 0.00% |
| WFG | 23.99% | $7.66B | +25.03% | 1.30% |
| KSS | 23.59% | $1.82B | -29.22% | 11.92% |
| KFY | 23.38% | $4.00B | +51.42% | 1.81% |
| BV | 23.30% | $1.58B | +127.29% | 0.00% |
| MEG | 23.22% | $645.54M | -40.69% | 0.00% |
| URGN | 23.15% | $487.40M | -7.82% | 0.00% |
| HOUS | 23.05% | $485.10M | -11.56% | 0.00% |
| YALA | 23.03% | $567.39M | -28.79% | 0.00% |
| KTOS | 22.99% | $3.96B | +37.74% | 0.00% |
| PATK | 22.90% | $2.98B | +58.25% | 1.64% |
| VIRC | 22.78% | $262.42M | +153.70% | 0.52% |
| EXC | 22.71% | $39.50B | +1.16% | 3.86% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ATUS | -<0.01% | $1.19B | +12.61% | 0.00% |
| SVC | -0.01% | $453.28M | -61.80% | 22.26% |
| HBM | -0.01% | $3.21B | +102.89% | 0.16% |
| LLYVK | -0.01% | $6.54B | +102.13% | 0.00% |
| GRPN | -0.02% | $365.86M | -8.73% | 0.00% |
| BZUN | -0.03% | $135.72M | -18.77% | 0.00% |
| EVTC | 0.03% | $2.29B | -0.85% | 0.55% |
| HCI | 0.03% | $1.16B | +28.66% | 1.44% |
| AMBA | -0.03% | $2.53B | +11.23% | 0.00% |
| WHF | -0.04% | - | - | 14.69% |
| MKSI | -0.05% | $7.65B | +46.21% | 0.77% |
| EPRT | 0.05% | $5.87B | +41.29% | 3.42% |
| OXM | -0.06% | $1.20B | -18.39% | 3.46% |
| BHR | -0.06% | $224.85M | +59.43% | 5.85% |
| UWMC | 0.07% | $575.58M | +7.89% | 6.63% |
| GYRE | -0.08% | $1.10B | -27.06% | 0.00% |
| NKLA | -0.08% | $123.56M | -92.80% | 0.00% |
| RSG | -0.09% | $67.03B | +33.78% | 1.01% |
| ECL | 0.09% | $68.93B | +30.42% | 0.93% |
| FTNT | 0.10% | $72.06B | +77.50% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ARLP | -20.93% | $3.57B | +27.36% | 9.97% |
| HCP | -15.45% | $6.87B | +62.04% | 0.00% |
| NGL | -14.90% | $587.46M | +8.80% | 0.00% |
| GFL | -14.79% | $18.01B | +56.26% | 0.12% |
| TGLS | -14.54% | $3.66B | +125.92% | 0.54% |
| ASR | -13.73% | $7.37B | +19.94% | 0.00% |
| CMTL | -13.57% | $91.22M | -73.99% | 0.00% |
| TSLA | -13.43% | $1.09T | +45.02% | 0.00% |
| PHG | -13.28% | $24.64B | +28.81% | 0.00% |
| TD | -12.26% | $97.71B | -8.24% | 5.36% |
| MNR | -10.80% | $1.70B | -6.89% | 15.55% |
| PULM | -10.53% | $22.32M | +230.27% | 0.00% |
| GKOS | -10.33% | $7.77B | +123.36% | 0.00% |
| TPIC | -10.26% | $92.75M | -14.66% | 0.00% |
| THS | -10.03% | $1.81B | -14.53% | 0.00% |
| BOOT | -9.95% | $4.16B | +91.77% | 0.00% |
| XOS | -9.77% | $32.60M | -58.61% | 0.00% |
| LPLA | -9.69% | $24.20B | +42.81% | 0.37% |
| GE | -9.62% | $193.41B | +87.35% | 0.51% |
| GUG | -9.31% | - | - | 9.12% |
ETF's related to NXTC
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| HDRO | -0.19% | $164.26M | 0.3% |
| VCAR | -0.20% | $10.47M | 1.2% |
| BOXX | 0.27% | $4.43B | 0.1949% |
| TPMN | -0.29% | $40.73M | 0.65% |
| CMDY | 0.34% | $285.76M | 0.28% |
| FTGC | 0.40% | $2.21B | 1.02% |
| URNM | 0.51% | $1.71B | 0.75% |
| FLTR | -0.55% | $1.79B | 0.14% |
| MINT | -0.63% | $11.62B | 0.35% |
| ESPO | 0.76% | $275.42M | 0.56% |
| BCD | 0.77% | $245.10M | 0.3% |
| SMMU | 0.80% | $624.62M | 0.35% |
| BCI | 0.92% | $1.20B | 0.26% |
| GCC | 0.96% | $135.83M | 0.55% |
| CSHI | -1.03% | $486.73M | 0.38% |
| HYZD | -1.10% | $161.68M | 0.43% |
| DBA | -1.26% | $768.98M | 0.93% |
| NFLT | 1.34% | $198.56M | 0.5% |
| ULST | 1.41% | $535.66M | 0.2% |
| XBIL | 1.42% | $637.84M | 0.15% |
News
Yahoo
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfec
Yahoo
Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results. “T
Yahoo
Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-endAdditional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today repor
Yahoo
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with p
Yahoo
Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phas
Yahoo
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.